- Most reported remissions are on-treatment clinical remission with modest placebo-adjusted benefit and persistent airway structural abnormalities, centred on T2-high asthma.
- Biological remission occurs in a minority and often dissociates from clinical control; higher baseline eosinophils and shorter disease duration predict attainment.
- Off-treatment remission is nearly absent; withdrawal trials show relapse, so disease modification requires standardised definitions, proven structural reversal and tested withdrawal.
Ann Allergy Asthma Immunol. 2026 Sep 24:S1081-1206(26)01198-1. doi: 10.1016/j.anai.2026.09.736. Online ahead of print.
ABSTRACT
Biologic therapies have made asthma remission an explicit treatment goal. Yet whether on-treatment remission represents genuine disease modification, or merely effective suppression, remains unresolved. This review presents a disease-modification evidence ladder (clinical, biological, structural and off-treatment remission) to map the gap between reported attainment and mechanistic proof. We synthesise trial and real-world data on remission rates, biomarker trajectories, airway remodelling and withdrawal outcomes. Two themes recur: the type 2 (T2) endotype dependence of current definitions, and the placebo-adjusted effect that any modification claim must clear. Most reported remission outcomes represent the lowest rung of this framework, on-treatment clinical remission, with modest placebo-adjusted differences in remission rates and persistent structural airway abnormalities.Biological remission is attained by a minority and dissociates from clinical control; baseline eosinophils and disease duration predict who reaches it. Structural gains, including reversal of fixed airflow obstruction and mucus plugging, are documented. But hard remodelling endpoints remain incompletely reversed, and trials with structural primary outcomes are still reporting. The decisive evidence, off-treatment remission, is nearly absent: the two randomised withdrawal trials show relapse, not durable cure. The entire construct is anchored in T2-high asthma. Its definitions cannot be applied to, and no targeted therapy exists for, the T2-low minority. Remission as currently demonstrated is on-treatment suppression of a structurally persistent, endotype-restricted disease. It will become a defensible modification claim only under four conditions: standardised definitions that separate drug effect from placebo, proven structural reversal, tested withdrawal after higher-rung remission, and extension of the concept beyond type 2 inflammation.
PMID:42785550 | DOI:10.1016/j.anai.2026.09.736
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
